4篇
您的检索式：作者名="Barbara Hauser"
|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 1,8-cineol inhibits nuclear translocation of NF-κB p65 and NF-κB-dependent transcriptional activity显示文摘 | Johannes F.-W. Greiner Janine Müller Marie-Theres Zeuner Stefan Hauser Thorsten Seidel Christin Klenke Lena-Marie Grunwald Timo Schomann Darius Widera Holger Sudhoff Barbara Kaltschmidt Christian Kaltschmidt | 2013 | BBA - Molecular Cell Research2013，，： | 1 |
| 2 | Determination of organophosphorus pesticides using membrane-assisted solvent extraction combined with large volume injection-gas chromatography-mass spectrometric detection显示文摘 | Manuela Schellin Barbara Hauser Peter Popp | 2004 | Journal of Chromatography A2004，1040，： | 1 |
| 3 | Determination of organophosphorus pesticides using membrane-assisted solvent extraction combined with large volume injection-gas chromatography-mass spectrometric detection显示文摘 | Manuela Schellin Barbara Hauser Peter Popp | 2004 | Journal of Chromatography A2004，1040，： | 1 |
| 4 | Real-world performance analysis of a novel computational method in the precision oncology of pediatric tumors显示文摘Background The utility of routine extensive molecular profiling of pediatric tumors is a matter of debate due to the high number of genetic alterations of unknown significance or low evidence and the lack of standardized and personalized decision support methods.Digital drug assignment(DDA)is a novel computational method to prioritize treatment options by aggregating numerous evidence-based associations between multiple drivers,targets,and targeted agents.DDA has been validated to improve personalized treatment decisions based on the outcome data of adult patients treated in the SHIVA01 clinical trial.The aim of this study was to evaluate the utility of DDA in pediatric oncology.Methods Between 2017 and 2020,103 high-risk pediatric cancer patients(<21 years)were involved in our precision oncology program,and samples from 100 patients were eligible for further analysis.Tissue or blood samples were analyzed by whole-exome(WES)or targeted panel sequencing and other molecular diagnostic modalities and processed by a software system using the DDA algorithm for therapeutic decision support.Finally,a molecular tumor board(MTB)evaluated the results to provide therapy recommendations.Results Of the 100 cases with comprehensive molecular diagnostic data,88 yielded WES and 12 panel sequencing results.DDA identified matching off-label targeted treatment options(actionability)in 72/100 cases(72%),while 57/100(57%)showed potential drug resistance.Actionability reached 88%(29/33)by 2020 due to the continuous updates of the evidence database.MTB approved the clinical use of a DDA-top-listed treatment in 56 of 72 actionable cases(78%).The approved therapies had significantly higher aggregated evidence levels(AELs)than dismissed therapies.Filtering of WES results for targeted panels missed important mutations affecting therapy selection.Conclusions DDA is a promising approach to overcome challenges associated with the interpretation of extensive molecular profiling in the routine care of high-risk pediatric cancers.Knowledgebase updates enable automatic interpretation of a continuously expanding gene set,a“virtual”panel,filtered out from genome-wide analysis to always maximize the performance of precision treatment planning. | Barbara Vodicska Júlia Déri Dóra Tihanyi Edit Várkondi EnikőKispéter Róbert Dóczi Dóra Lakatos Anna Dirner Mátyás Vidermann Péter Filotás Réka Szalkai-Dénes István Szegedi Katalin Bartyik Krisztina Míta Gábor Réka Simon Péter Hauser György Péter Csongor Kiss Miklós Garami István Peták | 2023 | World Journal of Pediatrics2023，19，10： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员